<DOC>
	<DOCNO>NCT01518127</DOCNO>
	<brief_summary>The purpose study evaluate behavior intravitreal injection autologous bone marrow stem cell patient age relate macular degeneration .</brief_summary>
	<brief_title>Intravitreal Bone Marrow-Derived Stem Cells Patients With Macular Degeneration</brief_title>
	<detailed_description>A prospective phase I/II , nonrandomized open-label study agen relate macular degeneration Stargartd patient best-corrected ETDRS visual acuity ( BCVA ) bad 20/200 . Standardized ophthalmic evaluation perform baseline week 1 , 4,12 24 ( Â±1 ) follow intravitreal injection 10 x 106 bone marrow stem cells/ 0,1ml . Three measure use evaluate short-term safety intravitreal bone marrow stem cell : 1 ) severe visual loss , define drop 15 letter ETDRS visual acuity scale ; 2 ) decrease ERG response ; 3 ) decrease 5 square degree visual field ; secondary safety outcome : 1 ) increase intra-ocular inflammation define herein anterior chamber cell flare high 3+ 1 month injection accord classification described elsewhere ; 2 ) decrease CMT 50um ; 3 ) genesis abnormal tissue ( teratoma ) tumor ; 4 ) qualitative change retinal choroidal perfusion , like macular nonperfusion . Secondary outcome measure use evaluate short-term efficiency intravitreal Bone Marrow Stem Cells : 1 ) improvement ERG response ; 2 ) increase visual field : 3 ) increase CSMT &gt; 50um related macular edemar choroidal neovascularization ; 4 ) increase &gt; 5 letter BCVA</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Male female AMD Stargartd patient 18 80 year old , inclusive . In either eye , diagnosis geographic atrophy choroidal neovascularization due AMD ETDRS best correct visual acuity 60 letter bad study eye . Retinal disease AMD study eye , investigator 's opinion , may pose safety risk interfere study . Choroidal neovascularization due cause AMD . In study eye , medium opacity interfere fundus image likely require surgery study period . Any following treatment study eye within 14 day prior dose : ranibizumab ( Lucentis ) , bevacizumab ( Avastin ) , pegaptanib ( Macugen ) , VEGF inhibitor ; OR likely requirement one treatment within 14 day LFG316 administration . Any follow within 30 day prior dose : photodynamic therapy treatment study eye ; extrafoveal juxtafoveal thermal laser photocoagulation study eye ; systemic topical ( ophthalmic ) steroid use study eye ; bacterial keratitis study eye ; OR intraocular surgery ( include cataract surgery ) fellow eye . Any follow within 90 day prior dose : intraocular surgery ( include cataract surgery ) study eye ; OR intravitreal periocular corticosteroid injection study eye . Participation another interventional clinical study , use experimental treatment AMD investigational new drug within 12 week prior start study treatment . Clinical trial solely involve overthecounter vitamin , supplement , diet exclude patient study participation . Any medical condition likely interfere patient 's participation study , likely cause serious adverse event study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Macular Degeneration</keyword>
</DOC>